Tadalafil
Product Images NDC 50090-4753

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 50090-4753). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Tadalafil Tablets (Bf07616c 918b 40b7 8ffb 7c6a12cd64e5 01)

Chemical structure diagram of tadalafil, depicting the molecular arrangement of atoms including rings and functional groups typical of this active pharmaceutical ingredient.*

FDA Label Image

Tadalafil Tablets (Bf07616c 918b 40b7 8ffb 7c6a12cd64e5 02)

Four line graphs comparing the difference in blood pressure (Tadalafil minus Placebo) over time (0 to 96 hours) for standing systolic, standing diastolic, supine systolic, and supine diastolic blood pressures. Each graph shows measurement differences in mmHg with error bars indicating variability at several time points.*

FDA Label Image

Tadalafil Tablets (Bf07616c 918b 40b7 8ffb 7c6a12cd64e5 03)

This figure presents two line graphs comparing standing and supine systolic blood pressure (mmHg) over 24 hours post-dose with Tadalafil 20 mg and doxazosin 8 mg versus placebo and doxazosin 8 mg. Both graphs show blood pressure changes on the y-axis and time post-dose in hours on the x-axis, highlighting the effects of the treatments over time.*

FDA Label Image

Tadalafil Tablets (Bf07616c 918b 40b7 8ffb 7c6a12cd64e5 04)

A line graph showing changes in systolic blood pressure (mmHg) over 12 hours after administration of 20 mg tadalafil or placebo along with 8 mg doxazosin at 08:00. It compares four groups: tadalafil at 08:00 with doxazosin, placebo at 08:00 with doxazosin, tadalafil at 20:00 with doxazosin, and placebo at 20:00 with doxazosin.*

FDA Label Image

Tadalafil Tablets (Bf07616c 918b 40b7 8ffb 7c6a12cd64e5 05)

A line graph depicting plasma tadalafil concentration (µg/L) over time (hours) for three treatment groups: single 20-mg tadalafil dose, single 5-mg tadalafil dose, and once-daily 5-mg tadalafil following 5 consecutive days of administration. The graph shows concentration changes across a 120-hour period with error bars indicating variability.*

FDA Label Image

Tadalafil Tablets (Bf07616c 918b 40b7 8ffb 7c6a12cd64e5 06)

A line graph comparing the change from baseline in IPSS total score over 12 weeks of treatment between Tadalafil 5 mg and placebo. The graph shows larger decreases in IPSS scores with Tadalafil than placebo, with timepoints marked at 0, 4, 8, and 12 weeks.*

FDA Label Image

Tadalafil Tablets (Bf07616c 918b 40b7 8ffb 7c6a12cd64e5 07)

A line graph showing the change from baseline in IPSS total score over a 12-week treatment period. It compares Tadalafil 5 mg to placebo, with Tadalafil represented by a solid line and placebo by a dashed line. The graph indicates a greater reduction in IPSS total score with Tadalafil, with significance marked at p<0.01.*

FDA Label Image

Tadalafil Tablets (Bf07616c 918b 40b7 8ffb 7c6a12cd64e5 08)

A line graph titled 'Weeks of Therapy' comparing least-squares mean changes from baseline in two groups over 26 weeks. One group receives Tadalafil/Finasteride, and the other receives Placebo/Finasteride. The graph shows greater negative change with Tadalafil/Finasteride at weeks 4, 12, and 26, with statistical significance indicated by annotations (p < 0.001 and p < 0.05).*

FDA Label Image

Tadalafil Tablets (Bf07616c 918b 40b7 8ffb 7c6a12cd64e5 09)

A line graph comparing change from baseline in IPSS total score over 12 weeks of treatment for Tadalafil 5mg versus placebo. The x-axis represents treatment duration in weeks, and the y-axis shows change in IPSS score. Tadalafil shows a greater decrease in score over time compared to placebo.*

FDA Label Image

Label Image (Lbl500904753)

Tadalafil 5 mg tablet bottle label from A-S Medication Solutions. The label states each film-coated tablet contains 5 mg of Tadalafil USP. Storage instructions specify 68 to 77 degrees Fahrenheit. The package contains 90 tablets. The label includes a lot number, product code, and a QR code for dosage instructions.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.